Kevin Zhou MD , Wendimagegn Alemayehu PhD , Sarah Rathwell MSc , Finlay A. McAlister MD, MSc , Heather Ross MD, MHSc , Jorge Escobedo MD , Clara Saldarriaga MD , Eloisa Colin-Ramirez PhD , Peter Macdonald MD , Joanne Arcand PhD, RD , Richard Troughton MBChB , Justin A. Ezekowitz MBBCh, MSc , SODIUM-HF Investigators
{"title":"The relationship of diuretics and dietary sodium in patients with heart failure: an analysis of the SODIUM-HF trial","authors":"Kevin Zhou MD , Wendimagegn Alemayehu PhD , Sarah Rathwell MSc , Finlay A. McAlister MD, MSc , Heather Ross MD, MHSc , Jorge Escobedo MD , Clara Saldarriaga MD , Eloisa Colin-Ramirez PhD , Peter Macdonald MD , Joanne Arcand PhD, RD , Richard Troughton MBChB , Justin A. Ezekowitz MBBCh, MSc , SODIUM-HF Investigators","doi":"10.1016/j.ahj.2024.11.019","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>SODIUM-HF was a large clinical trial testing dietary sodium restriction compared to usual care in patients with heart failure that showed no reduction in clinical events. It has been suggested that diuretic doses in response to dietary sodium modification may have influenced the trial results.</div></div><div><h3>Objective</h3><div>We assessed the effects of baseline diuretic dose and diuretic dose changes on clinical outcomes in the SODIUM-HF trial.</div></div><div><h3>Methods</h3><div>Diuretics were converted to furosemide-equivalent diuretic total daily doses. Furosemide dose was treated as a continuous variable and also stratified into 0mg, 1mg to 39mg, 40mg, 41mg to 80mg, and > 80mg daily. The baseline diuretic dose and change in diuretic dose were assessed and correlated with dietary sodium restriction and changes in dietary sodium intake. We then examined the relationship between diuretic dosing and the primary outcomes of SODIUM-HF (cardiovascular-related emergency department visit, cardiovascular-related hospitalization, and all-cause mortality).</div></div><div><h3>Results</h3><div>Of the 806 patients enrolled in the SODIUM-HF trial, 784 had known diuretic status at baseline: 209 patients (26.7%) with 0mg, 134 patients (17%) with 1mg to 39mg, 205 patients (26.1%) with 40mg, 118 patients (15.1%) with 41mg to 80mg, and 118 patients (15.1%) with > 80mg. No correlation was found between dietary sodium intake and diuretic dose, either at baseline or change throughout the study (<em>P > .</em>05). For the primary outcomes, the 2-year risk of primary outcomes was strongly correlated with diuretic dose at baseline across the overall SODIUM-HF population (<em>P < .</em>001). No significant association was found between the treatment arm and the risk of primary outcomes, within each baseline diuretic dose range or with change in diuretic dose (both <em>P > .</em>05).</div></div><div><h3>Conclusions</h3><div>Although a higher baseline diuretic dose was associated with worse clinical outcomes, no association was found between dietary sodium restriction, baseline or change in diuretic dose and the primary outcomes.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"281 ","pages":"Pages 49-58"},"PeriodicalIF":3.7000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002870324003211","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
SODIUM-HF was a large clinical trial testing dietary sodium restriction compared to usual care in patients with heart failure that showed no reduction in clinical events. It has been suggested that diuretic doses in response to dietary sodium modification may have influenced the trial results.
Objective
We assessed the effects of baseline diuretic dose and diuretic dose changes on clinical outcomes in the SODIUM-HF trial.
Methods
Diuretics were converted to furosemide-equivalent diuretic total daily doses. Furosemide dose was treated as a continuous variable and also stratified into 0mg, 1mg to 39mg, 40mg, 41mg to 80mg, and > 80mg daily. The baseline diuretic dose and change in diuretic dose were assessed and correlated with dietary sodium restriction and changes in dietary sodium intake. We then examined the relationship between diuretic dosing and the primary outcomes of SODIUM-HF (cardiovascular-related emergency department visit, cardiovascular-related hospitalization, and all-cause mortality).
Results
Of the 806 patients enrolled in the SODIUM-HF trial, 784 had known diuretic status at baseline: 209 patients (26.7%) with 0mg, 134 patients (17%) with 1mg to 39mg, 205 patients (26.1%) with 40mg, 118 patients (15.1%) with 41mg to 80mg, and 118 patients (15.1%) with > 80mg. No correlation was found between dietary sodium intake and diuretic dose, either at baseline or change throughout the study (P > .05). For the primary outcomes, the 2-year risk of primary outcomes was strongly correlated with diuretic dose at baseline across the overall SODIUM-HF population (P < .001). No significant association was found between the treatment arm and the risk of primary outcomes, within each baseline diuretic dose range or with change in diuretic dose (both P > .05).
Conclusions
Although a higher baseline diuretic dose was associated with worse clinical outcomes, no association was found between dietary sodium restriction, baseline or change in diuretic dose and the primary outcomes.
期刊介绍:
The American Heart Journal will consider for publication suitable articles on topics pertaining to the broad discipline of cardiovascular disease. Our goal is to provide the reader primary investigation, scholarly review, and opinion concerning the practice of cardiovascular medicine. We especially encourage submission of 3 types of reports that are not frequently seen in cardiovascular journals: negative clinical studies, reports on study designs, and studies involving the organization of medical care. The Journal does not accept individual case reports or original articles involving bench laboratory or animal research.